Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801)
Related Posts
Samorodnitsky S, Campbell K, Little A, Ling W, Zhao N, Chen YC, Wu MC. Detecting clinically relevant topological structures in multiplexed spatial proteomics using TopKAT.[...]
Sun J, Nidadavolu LS, Hsu HY, Rajagopal RG, Astemborski J, Wu Y, Jiang Y, Sacha JB, Kievit P, Jamieson BD, Roberts CT, Kirk GD, Brown[...]
Park D, Varda M, Yeremian S, Hwang A, Huang C. CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis. Target[...]